{"references": ["J.F.-W. Chan, K.K.-W. To, H. Tse, D.-Y. Jin, and K.-Y. Yuen, Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 21 (2013) 544\u2013555. doi: 10.1016/j.tim.2013.05.005.", "J. Cui, F. Li, and Z.-L. Shi, Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17 (2019) 181\u2013192. doi: 10.1038/s41579-018-0118-9.", "O. Baysal, R.S. Silme, C. Karaaslan, and A. Ignatov, Genetic uniformity of a specific region in SARS-CoV-2 genome and in-silico target-oriented repurposing of N-Acetyl-D-Glucosamine. Fresenius Environ. Bull. 30 (2021) 2848\u20132857.", "S. Pushpakom, F. Iorio, P.A. Eyers, K.J. Escott, S. Hopper, A. Wells, et al., Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18 (2019) 41\u201358. doi: 10.1038/nrd.2018.168.", "National Center for Biotechnology Information. PubChem Compound Summary for CID 439174, N-Acetyl-D-Glucosamine. Retrieved January 29, 2021 from https://pubchem.ncbi.nlm.nih.gov/compound/N-Acetyl-D-Glucosamine.", "J. Lan, J. Ge, J. Yu, S. Shan, H. Zhou, S. Fan, et al., Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 581 (2020) 215\u2013220. doi: 10.1038/s41586-020-2180-5.", "S. Kang, M. Yang, Z. Hong, L. Zhang, Z. Huang, X. Chen, et al., Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm. Sin. B. 10 (2020) 1228-1238. doi: 10.1016/j.apsb.2020.04.009.", "M. McCallum, A.C. Walls, J.E. Bowen, D. Corti, and D. Veesler, Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. Nat. Struct. Mol. Biol., 27 (2020) 942\u2013949. doi: 10.1038/s41594-020-0483-8.", "M. Schmidt and T. Malla, SARS-CoV-2 Main protease 3CLpro, room temperature, damage free xfel monoclinic structure. (2020). doi: 10.2210/pdb7jvz/pdb.", "T.A. Halgren, Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules. J. Comput. Chem. 17 (1996) 616\u2013641. doi: 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X.", "E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, et al., UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem. 25 (2004) 1605\u20131612. doi: 10.1002/jcc.20084.", "G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, et al., AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30 (2009) 2785\u20132791. doi: 10.1002/jcc.21256.", "O. Trott and A.J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 31 (2010) 455\u2013461. doi: 10.1002/jcc.21334.", "L.S. Dodda, I. Cabeza de Vaca, J. Tirado-Rives, and W.L. Jorgensen, LigParGen web server: an automatic OPLS-AA parameter generator for organic ligands. Nucleic Acids Res. 45 (2017) W331\u2013W336. doi: 10.1093/nar/gkx312.", "L.S. Dodda, J.Z. Vilseck, J. Tirado-Rives, and W.L. Jorgensen, 1.14*CM1A-LBCC: Localized bond-charge corrected CM1A charges for condensed-phase simulations. J. Phys. Chem. B, 121 (2017) 3864\u20133870. doi: 10.1021/acs.jpcb.7b00272.", "W.L. Jorgensen and J. Tirado-Rives, Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. Proc. Natl. Acad. Sci. 102 (2005) 6665\u20136670. doi: 10.1073/pnas.0408037102.", "W. Humphrey, A. Dalke, and K. Schulten, VMD: visual molecular dynamics. J. Mol. Graph. 14 (1996) 33-38. doi: 10.1016/0263-7855(96)00018-5.", "J.C. Phillips, D.J. Hardy, J.D.C. Maia, J.E. Stone, J.V. Ribeiro, et al., Scalable molecular dynamics on CPU and GPU architectures with NAMD. J. Chem. Phys. 153 (2020) 044130. doi: 10.1063/5.0014475.", "S. Jo, T. Kim, V. G. Iyer, and W. Im, CHARMM-GUI: A web-based graphical user interface for CHARMM. J. Comput. Chem. 29 (2008) 1859\u20131865. doi: 10.1002/jcc.20945.", "Schr\u00f6dinger, LLC (2010) The PyMOL molecular graphics system, version 1.3r1. Schr\u00f6dinger, LLC, Portland, Oregon.", "A.-T. Ton, F. Gentile, M. Hsing, F. Ban, and A. Cherkasov, Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. Mol. Inform. 39 (2020) 2000028. doi: 10.1002/minf.202000028.", "Z. Xu, C. Peng, Y. Shi, Z. Zhu, K. Mu, X. Wang, et al., Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv. (2020) 2020.01.27.921627. doi: 10.1101/2020.01.27.921627.", "X. Liu and X.-J. Wang, Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J. Genet. Genomics. 47 (2020) 119\u2013121. doi: 10.1016/j.jgg.2020.02.001.", "Y. Li, J. Zhang, N. Wang, H. Li, Y. Shi, G. Guo, et al., Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening. bioRxiv. (2020) 2020.01.28.922922. doi: 10.1101/2020.01.28.922922.", "D.D. Nguyen, K. Gao, J. Chen, R. Wang, and G.-W. Wei, Potentially highly potent drugs for 2019-nCoV. bioRxiv. (2020) 2020.02.05.936013. doi: 10.1101/2020.02.05.936013.", "S. Talluri, Molecular docking and virtual screening based prediction of drugs for COVID-19. Comb. Chem. High Throughput Screen. 24 (2021) 716\u2013728. doi: 10.2174/1386207323666200814132149.", "Y.W. Chen, C.-P.B. Yiu, and K.-Y. Wong, Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research. 9 (2020) 129. doi: 10.12688/f1000research.22457.2.", "A. Fischer, M. Sellner, S. Neranjan, M.A. Lill, and M. Smie\u0161ko, Potential inhibitors for novel Coronavirus protease identified by virtual screening of 606 million compounds. ChemRxiv. (2020) doi: 10.26434/chemrxiv.11923239.v2.", "D. Gentile, V. Patamia, A. Scala, M.T. Sciortino, A. Piperno, and A. Rescifina, Putative inhibitors of SARS-CoV-2 main protease from a library of marine natural products: a virtual screening and molecular modeling study. Mar. Drugs. 18 (2020) 225. doi: 10.3390/md18040225.", "S. Adem, V. Eyupoglu, I. Sarfraz, A. Rasul, and M. Ali, Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: an in silico strategy unveils a hope against CORONA. Preprints. (2020) 2020030333. doi: 10.20944/preprints202003.0333.v1.", "G. Wang and W. Zhu, Molecular docking for drug discovery and development: a widely used approach but far from perfect. Future Med. Chem. 8 (2016) 1707\u20131710. doi: 10.4155/fmc-2016-0143.", "M. De Vivo, M. Masetti, G. Bottegoni, and A. Cavalli, Role of molecular dynamics and related methods in drug discovery. J. Med. Chem. 59 (2016) 4035\u20134061. doi: 10.1021/acs.jmedchem.5b01684.", "M.H. Cheng, J.M. Krieger, B. Kaynak, M. Arditi, and I. Bahar, Impact of South African 501.V2 variant on SARS-CoV-2 spike infectivity and neutralization: a structure-based computational assessment. bioRxiv. (2021) 2021.01.10.426143. doi: 10.1101/2021.01.10.426143.", "C. Soliman, A.K. Walduck, E. Yuriev, J.S. Richards, C. Cywes-Bentley, G.B. Pier, et al., Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly-N-acetylglucosamine. J. Biol. Chem. 293 (2018) 5079\u20135089. doi: 10.1074/jbc.RA117.001170.", "D.-J. Scheffers and M.G. Pinho, Bacterial cell wall synthesis: new insights from localization studies. Microbiol. Mol. Biol. Rev. 69 (2005) 585\u2013607. doi: 10.1128/MMBR.69.4.585-607.2005.", "B.E. Chechik and I. Brockhausen, Immunochemistry of highly branched N-glycans. Terminal N-acetyl-D-glucosamine (GlcNAc) cluster antigens contain epitopes composed of terminal GlcNAc residues linked to mannose. Biochem. Cell Biol. 66 (1988) 1333\u20131341. doi: 10.1139/o88-154.", "G.B.E. Stewart-Jones, C. Soto, T. Lemmin, G.-Y. Chuang, A. Druz, R. Kong, et al., Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell. 165 (2016) 813\u2013826. doi: 10.1016/j.cell.2016.04.010.", "K. Hulikova, V. Benson, J. Svoboda, P. Sima, and A. Fiserova, N-Acetyl-D-glucosamine-coated polyamidoamine dendrimer modulates antibody formation via natural killer cell activation. Int. Immunopharmacol. 9 (2009) 792\u2013799. doi: 10.1016/j.intimp.2009.03.007."]}

Background: The causative agent of virus disease outbreak in the world identified as SARS-CoV-2 leads to a severe respiratory illness similar to that of SARS and MERS. The pathogen outbreak was declared as a pandemic and by the time of this article, it has claimed 2.19 million lives. Computational biology research has provided a lot of insight into many of the structural and functional proteins of the virus and the efforts continue. Methods: We performed molecular docking of several SARS-CoV-2 proteins that are responsible for its pathogenicity against N-acetyl-D-glucosamine via AutoDock Vina and further analyzed the docked poses with molecular dynamics, we also performed a similar experiment for both SARS-CoV-2 and anti-Staphylococcus aureus neutralizing antibodies to establish the potential N-acetyl-D-glucosamine hold in inducing the immune system against the virus. Results: Our new molecular docking and molecular dynamic analysis results have confirmed that SARS-CoV-2 spike receptor-binding domain (PDB: 6M0J), crystal structure of RNA-binding domain of nucleocapsid phosphoprotein from SARS-CoV-2 monoclinic crystal form (PDB: 6WKP), electron microscopy structure of refusion SARS-CoV-2 S ectodomain trimer covalently stabilized in the closed conformation (PDB: 6X79), and X-ray diffraction structure of SARS-CoV-2 main protease 3clpro at room temperature (damage-free XFEL monoclinic, PDB: 7JVZ), and N-acetyl-D-glucosamine could bind on these proteins that play an important role in SARS-CoV-2’s infection. Moreover, our molecular docking analysis data support a strong protein-ligand interaction of N-acetyl-D-glucosamine. These results were confirmed with molecular dynamics studies and the conformational modeling could be used to predict the possible protein-ligand interactions. Additionally, docking analysis against the D614G mutant of the virus have shown that N-acetyl-D-glucosamine affinity was not affected by mutations in the virus’ receptor binding domain. Furthermore, our analysis on the affinity of D-GlcNAc towards human antibodies has shown that it could potentially bind to both SARS-CoV-2 proteins and antibodies hence further induce the immune system against the viral infection. Conclusion: Based on our predictive modelling work, N-acetyl-D-glucosamine holds the potential to inhibit several SARS-CoV-2 proteins as well as induce an immune response against the virus in host system.